Anzeige
Meldung des Tages: J.P. Morgan sieht 5.000–6.000 US-Dollar Gold!!!
Zurück
XOMA
Beiträge:
97
Zugriffe: 36.850 / Heute: 16
Zugriffe: 36.850 / Heute: 16
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +74,06%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +57,12%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +57,11%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,39%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +47,15%
www.fool.com/investing/general/2015/11/06/...are-crashing.aspx
So what: A high profile failure of XOMA's monoclonal antibody gevokizumab for Behcet's disease uveitis in phase 3 in July led to XOMA's shares plummeting from $5 to less than $1, but shares have regained some of their losses more recently following news in October that XOMA had inked a licensing deal with Novartis (NYSE:NVS).
The Novartis deal included an upfront cash payment of $37 million in exchange for global rights to XOMA's TGFb antibody program and extended the maturity date for a $13.5 million note due to Novartis to September 2020.
In addition to the Novartis deal, XOMA also orchestrated a major restructuring of its operations in Q3 to eliminate costs in the wake of gevokizumab's disappointment. That restructuring includes the sale of its biologics manufacturing operation to Agenus for $5 million plus $1 million in Agenus stock and the divesting of its biodefense program, as well as lay-offs.
Overall, XOMA's R&D expenses dropped to $17.6 million from $20.2 million last year, and its SG&A costs totaled $5.6 million, up slightly from $5.4 million a year ago due to increased consulting costs tied to its deal with Novartis, which offset salary savings tied to the restructuring.
Now what: The company's restructuring focuses XOMA on its endocrine program, which includes XOMA 358, a therapy for the treatment of congenital hyperinsulinism that reduces insulin receptor activity.
Last quarter, XOMA kicked off phase 2 development of XOMA 358 by opening the first of two proof-of-concept studies. While we won't know whether or not XOMA 358 will succeed in these mid stage studies for a while, the company believes that its restructuring does give it the financial wiggle room necessary to fund its research and operations through 2017.
Although it's encouraging to know that XOMA has moved quickly to right size itself and reduce its cash burn, XOMA remains a high risk company that doesn't have any commercialized products. Since there's likely to be a long wait until we get actionable data on XOMA 358, I'm simply unwilling to take on the risk of buying shares on this sell-off.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here.
So what: A high profile failure of XOMA's monoclonal antibody gevokizumab for Behcet's disease uveitis in phase 3 in July led to XOMA's shares plummeting from $5 to less than $1, but shares have regained some of their losses more recently following news in October that XOMA had inked a licensing deal with Novartis (NYSE:NVS).
The Novartis deal included an upfront cash payment of $37 million in exchange for global rights to XOMA's TGFb antibody program and extended the maturity date for a $13.5 million note due to Novartis to September 2020.
In addition to the Novartis deal, XOMA also orchestrated a major restructuring of its operations in Q3 to eliminate costs in the wake of gevokizumab's disappointment. That restructuring includes the sale of its biologics manufacturing operation to Agenus for $5 million plus $1 million in Agenus stock and the divesting of its biodefense program, as well as lay-offs.
Overall, XOMA's R&D expenses dropped to $17.6 million from $20.2 million last year, and its SG&A costs totaled $5.6 million, up slightly from $5.4 million a year ago due to increased consulting costs tied to its deal with Novartis, which offset salary savings tied to the restructuring.
Now what: The company's restructuring focuses XOMA on its endocrine program, which includes XOMA 358, a therapy for the treatment of congenital hyperinsulinism that reduces insulin receptor activity.
Last quarter, XOMA kicked off phase 2 development of XOMA 358 by opening the first of two proof-of-concept studies. While we won't know whether or not XOMA 358 will succeed in these mid stage studies for a while, the company believes that its restructuring does give it the financial wiggle room necessary to fund its research and operations through 2017.
Although it's encouraging to know that XOMA has moved quickly to right size itself and reduce its cash burn, XOMA remains a high risk company that doesn't have any commercialized products. Since there's likely to be a long wait until we get actionable data on XOMA 358, I'm simply unwilling to take on the risk of buying shares on this sell-off.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here.
Wurde schon mehrfach gesagt.
XOMA - BOOMBOOMBOOM Short-Interests,Days to Cover
www.nasdaq.com/symbol/xoma/short-interest
www.nasdaq.com/symbol/xoma/short-interest
ih.advfn.com/...pid=nmona&article=69283222&symbol=XOMA
Link auf streetinsider.com!
75 mill market sale agreement!
75 mill market sale agreement!
ich habe mal alle deine geposteten Dollar-Zeichen zusammengezählt.
Kann ich jetzt davon ausgehen, dass es zu einem "Big Big Boig" Boing Bang reboind bis auf 16 $ kommt?
Kann ich jetzt davon ausgehen, dass es zu einem "Big Big Boig" Boing Bang reboind bis auf 16 $ kommt?
Und $ ich $ beobachte $ den $ Kurs $ und $ bin $ auf $ den $ großen $ Knall $ gespannt...
was gehen:
m.benzinga.com/article/...rrer=https%3A%2F%2Fwww.google.com%2F
Ein Kursziel von 6 $ ist mal eine Ansage !
m.benzinga.com/article/...rrer=https%3A%2F%2Fwww.google.com%2F
Ein Kursziel von 6 $ ist mal eine Ansage !
und Kursziele sind jetzt auch nicht sooo schlecht:
www.uptickanalyst.com/...asdaqxoma-perspective-on-the-stock-2/
The ratings are fully transparent and everyone has a open scorecard and record. The democratic platform helps understand crowd sentiment on a stock. Shares of XOMA Corporation (NASDAQ:XOMA) currently have an average rating of 4.5. This number is based on a 1 to 5 scare where 5 represents a Strong Buy and 1 represents a Strong Sell. Of the 16 active ratings, 3 have given the shares a Moderate Buy while 11 are recommending a Strong Buy.
Wall Street sell-side analysts that were polled are predicting that the company’s shares will reach $1.5 to $6 within the year. These are the most bearish and bullish numbers out of the consensus data compiled by Zacks. The consensus stock target currently stands at $3.1.
As for earnings, the Street is expecting that the firm will post earnings of $-0.14 per share for the current quarter. This is compared to the actual earnings of $-0.18 which the company most recently reported for the period ending on 2015-09-30. All eyes will be on the firm when they next report actual results on or around 2016-03-09.
www.uptickanalyst.com/...asdaqxoma-perspective-on-the-stock-2/
The ratings are fully transparent and everyone has a open scorecard and record. The democratic platform helps understand crowd sentiment on a stock. Shares of XOMA Corporation (NASDAQ:XOMA) currently have an average rating of 4.5. This number is based on a 1 to 5 scare where 5 represents a Strong Buy and 1 represents a Strong Sell. Of the 16 active ratings, 3 have given the shares a Moderate Buy while 11 are recommending a Strong Buy.
Wall Street sell-side analysts that were polled are predicting that the company’s shares will reach $1.5 to $6 within the year. These are the most bearish and bullish numbers out of the consensus data compiled by Zacks. The consensus stock target currently stands at $3.1.
As for earnings, the Street is expecting that the firm will post earnings of $-0.14 per share for the current quarter. This is compared to the actual earnings of $-0.18 which the company most recently reported for the period ending on 2015-09-30. All eyes will be on the firm when they next report actual results on or around 2016-03-09.
www.financial-market-news.com/...t-price-from-analysts/894415/
Shares of XOMA Corp (NASDAQ:XOMA) have been assigned an average rating of “Hold” from the ten brokerages that are currently covering the company, AnalystRatingsNetwork.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $3.26.
...
wer hier aktuell als Insider einkauft !
investors.xoma.com/sec.cfm
investors.xoma.com/sec.cfm
und das Jahresergenis 2015 raus. Bin sehr gespannt.
investors.xoma.com/releasedetail.cfm?ReleaseID=956849
investors.xoma.com/releasedetail.cfm?ReleaseID=956849
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Xoma Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 92 | Bausch Health - ehemals Valeant - u.a. Pharmawerte | macumba | M.Minninger | 25.07.24 09:14 | ||
2 | 96 | XOMA | achmadgülcan | macumba | 25.04.21 00:55 | |
| Xoma LTD | Uebelkraehe | 30.11.12 10:12 | ||||
| 2 | 31 | Xoma ist kein Pennystock mehr | CosmicTrade | Reggio Emilia | 17.09.12 16:08 | |
| 3 | 284 | Lieber mal ´ne XOMA, als vom MediaMarkt die Oma ! | baanbruch | CosmicTrade | 12.08.11 15:01 |